Form 4: Lifecore Biomedical Director Receives RSU Grant

Director Christopher S. Kiper of Lifecore Biomedical, Inc. was granted 25,907 restricted stock units as compensation for board service.

Summary

• Christopher S. Kiper, a director at Lifecore Biomedical, Inc., received a grant of 25,907 restricted stock units (RSUs).
• The RSUs vest on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders, provided it is at least 50 weeks from the grant date.
• The grant is part of standard director compensation for board service.
• Legion Partners Asset Management, where Mr. Kiper is a Managing Director, retains the economic interest in these securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation and ownership, which carries no significant sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to continued service on the Board of Directors.
• The value of the equity grant is subject to market volatility of the underlying common stock.

Future Outlook

The RSUs are expected to vest in June 2027, contingent upon the director's continued service on the Board.

Management Comments

• The reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.
• Legion Partners Asset Management is entitled to receive all economic interest in the securities granted to Mr. Kiper for his board service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice to ensure directors are incentivized to oversee company performance effectively.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for publicly traded companies in the biomedical sector.
• The vesting schedule of approximately one year is typical for annual director equity awards.

Related Party Transactions

• The filing discloses that Mr. Kiper serves on the Board as a representative of Legion Partners Asset Management, which holds the economic interest in the granted securities.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation disclosure.

Next Steps

• Vesting of the granted RSUs in June 2027.

Key Dates

Keywords

Lifecore Biomedical, LFCR, Form 4, Insider Trading, Director Compensation, Legion Partners